文献速递贫血与红细胞疾病MDS 与骨髓增殖性肿瘤

靶向tmprss6的GalNAc偶联19聚体siRNA SLN124可降低健康志愿者血浆铁并升高hepcidin水平

SLN124, a GalNAc conjugated 19-mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers.
PubMed 文献 · Am J Hematol · 2023-07-27

SLN124是一种靶向TMPRSS6的GalNAc偶联19聚体siRNA,通过肝脏靶向沉默TMPRSS6增加内源性hepcidin合成。该首次人体1期研究在24名健康志愿者中评估单次递增剂量SLN124(1.0、3.0、4.5 mg/kg)的安全性、耐受性、药代动力学和药效学。结果显示无严重或重度不良事件,大多数治疗中出现的不良事件为轻度,SLN124可剂量相关地持续降低血浆铁和转铁蛋白饱和度,并升高血浆hepcidin水平。

要点

  • SLN124在健康志愿者中单次皮下给药安全耐受,无严重或重度不良事件。
  • SLN124使血浆hepcidin水平升高,约在第29天达峰。
  • SLN124剂量相关地持续降低血浆铁和转铁蛋白饱和度,并降低网织红细胞生成、MCHC和MCV。

核心结论

  • SLN124单次皮下给药在健康志愿者中安全耐受,可升高血浆hepcidin并剂量相关地持续降低血浆铁和转铁蛋白饱和度。
  • 结果提示单次SLN124给药后对hepcidin及铁代谢血液学参数(血清铁和TSAT)的作用持续时间可达56天。

研究设计与样本

  • 首次人体、1期研究,评估单次递增剂量SLN124(1.0、3.0、4.5 mg/kg)在健康志愿者中的安全性、耐受性、药代动力学和药效学。
  • 24名参与者随机分入三个序贯队列,每队列8人,按6:2随机接受单次皮下注射SLN124或安慰剂。

主要发现

  • 无严重或重度不良事件,无因不良事件导致的停药,大多数治疗中出现的不良事件为轻度,包括一过性轻度注射部位反应,无需干预即缓解。
  • SLN124迅速吸收,所有治疗组的中位tmax为4-5小时,48小时时基本从血浆中清除。
  • 治疗组间血浆浓度呈超过剂量比例的增加。
  • 所有SLN124组中铁代谢标志物呈剂量相关效应,血浆hepcidin水平升高并于第29天左右达峰,随后血浆铁和转铁蛋白饱和度剂量相关地持续降低,网织红细胞生成、MCHC和MCV降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SLN124, an N-acetylgalactosamine conjugated 19-mer short interfering RNA, is being developed to treat iron-loading anemias (including beta-thalassemia and myelodysplastic syndromes) and myeloproliferative neoplasms (polycythemia vera). Through hepatic targeting and silencing of the TMPRSS6 gene, SLN124 increases endogenous hepcidin synthesis. This is the first clinical report of an siRNA targeting a component of iron homeostasis. This first-in-human, phase 1 study assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of SLN124 (1.0, 3.0, and 4.5 mg/kg) in healthy volunteers. Twenty-four participants were randomized in three sequential cohorts of eight subjects, each to receive a single dose of either SLN124 or placebo (6:2 randomization), administered subcutaneously. There were no serious or severe adverse events, or discontinuations due to adverse events, and most treatment-emergent adverse events were mild, including transient mild injection site reactions, resolving without intervention. SLN124 was rapidly absorbed, with a median tmax of 4-5 h across all treatment groups, and largely eliminated from plasma by 48 h. Plasma concentrations increased in a greater than dose proportional fashion between treatment groups. In all SLN124 groups, a dose-related effect was observed across iron metabolism markers, and across erythroid markers, SLN124 resulted in increased plasma hepcidin levels, peaking around Day 29, and consequent dose-related sustained reductions in plasma iron and transferrin saturation with decreased reticulocyte production, MCHC, and MCV. Results suggest duration of action lasting up to 56 days after a single SLN124 dose, on hepcidin and hematological parameters of iron metabolism (serum iron and TSAT).

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Porter JB, Scrimgeour A, Martinez A, et al. SLN124, a GalNAc conjugated 19-mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers. Am J Hematol. 2023. PMID: 37497888. doi:10.1002/ajh.27015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。